Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV [1] [2] [3] [4] [5].
In Vivo, Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (8 mg/kg, i.p., 4 times weekly, from week 18 to week 24) significantly reduced the number of tumors combined with BLZ945 in C57BL/6J mice with a Diethylnitrosamine (DEN) and Carbon tetrachloride (CCl4) induced hepatocellular carcinoma cancer[4]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (100-200 μg, i.p., once every 48 h, for 12 days) significantly reduces the amount of HIV virus in TKO-BLT mice infected with HIV virus[5].
In Vitro, Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (5 μg/mL, 16 h) significantly reduces the migration of THP-1 cells to infected enteroid-derived monolayers (EDMs)[1]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (10 μg/mL, 24 h) significantly reduces the enhancing effect of mesenchymal stromal/stem cells (MSCs) on natural killer (NK) cell IFN-γ secretion[2]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can inhibit the recruitment of CD8+ T cells by LILRB4 knockdown in BV2 cells[3].
References:
[1]. Sayed IM, et al. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 Sep;287(18):3967-3988.
[2]. Cui R, et al. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther. 2016 Jul 7;7(1):88.
[3]. Ma Y, et al. Microglia LILRB4 upregulation reduces brain damage after acute ischemic stroke by limiting CD8+ T cell recruitment. J Neuroinflammation. 2024 Aug 31;21(1):214.
[4]. Du Y, et al. ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. Adv Sci (Weinh). 2024 Dec;11(45):e2404756.
[5]. Packard TA, et al. CCL2: a Chemokine Potentially Promoting Early Seeding of the Latent HIV Reservoir. mBio. 2022 Oct 26;13(5):e0189122.
In Vivo, Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (8 mg/kg, i.p., 4 times weekly, from week 18 to week 24) significantly reduced the number of tumors combined with BLZ945 in C57BL/6J mice with a Diethylnitrosamine (DEN) and Carbon tetrachloride (CCl4) induced hepatocellular carcinoma cancer[4]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (100-200 μg, i.p., once every 48 h, for 12 days) significantly reduces the amount of HIV virus in TKO-BLT mice infected with HIV virus[5].
In Vitro, Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (5 μg/mL, 16 h) significantly reduces the migration of THP-1 cells to infected enteroid-derived monolayers (EDMs)[1]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) (10 μg/mL, 24 h) significantly reduces the enhancing effect of mesenchymal stromal/stem cells (MSCs) on natural killer (NK) cell IFN-γ secretion[2]. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can inhibit the recruitment of CD8+ T cells by LILRB4 knockdown in BV2 cells[3].
References:
[1]. Sayed IM, et al. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 Sep;287(18):3967-3988.
[2]. Cui R, et al. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients. Stem Cell Res Ther. 2016 Jul 7;7(1):88.
[3]. Ma Y, et al. Microglia LILRB4 upregulation reduces brain damage after acute ischemic stroke by limiting CD8+ T cell recruitment. J Neuroinflammation. 2024 Aug 31;21(1):214.
[4]. Du Y, et al. ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. Adv Sci (Weinh). 2024 Dec;11(45):e2404756.
[5]. Packard TA, et al. CCL2: a Chemokine Potentially Promoting Early Seeding of the Latent HIV Reservoir. mBio. 2022 Oct 26;13(5):e0189122.